{"log_id": 4566388426304886341, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 0.02146, "average": 0.934482, "min": 0.426701}, "location": {"width": 766, "top": 156, "height": 30, "left": 205}, "words": "观察到少Ⅱ【期代谢产物葡萄糖醛酸甙结合物和流酸结合物。思卡不是细胞色素"}, {"probability": {"variance": 0.000757, "average": 0.983685, "min": 0.903205}, "location": {"width": 373, "top": 198, "height": 25, "left": 216}, "words": "50(CYP450)酶系统的底物、抑制剂或诱导剂"}, {"probability": {"variance": 0.002648, "average": 0.974595, "min": 0.772125}, "location": {"width": 702, "top": 231, "height": 34, "left": 250}, "words": "在达到血浆峰浓度后,血药浓度以双指数方式下降,达到终末清除半衰期约需128"}, {"probability": {"variance": 0.0037, "average": 0.977471, "min": 0.646491}, "location": {"width": 768, "top": 272, "height": 33, "left": 197}, "words": "149小时药物积指数约为每天一次给药剂量的2倍,这表明其有效累积半衰期约为24"}, {"probability": {"variance": 1e-06, "average": 0.999217, "min": 0.998452}, "location": {"width": 40, "top": 320, "height": 22, "left": 199}, "words": "小时"}, {"probability": {"variance": 0.005298, "average": 0.962039, "min": 0.606246}, "location": {"width": 658, "top": 351, "height": 33, "left": 240}, "words": "本品主要以原形通过肾脏清除,清除率为给药量的6273%肾清除率为360-"}, {"probability": {"variance": 0, "average": 0.998044, "min": 0.998044}, "location": {"width": 23, "top": 349, "height": 24, "left": 1084}, "words": "品"}, {"probability": {"variance": 0.011375, "average": 0.951259, "min": 0.56715}, "location": {"width": 750, "top": 388, "height": 36, "left": 195}, "words": "471mL/min,且不依赖于给药剂量,这表明恩替卡韦同时通过肾小球滤过和网状小管分泌"}, {"probability": {"variance": 7e-06, "average": 0.995889, "min": 0.991284}, "location": {"width": 82, "top": 463, "height": 24, "left": 193}, "words": "特殊人群"}, {"probability": {"variance": 0.011214, "average": 0.96635, "min": 0.52952}, "location": {"width": 407, "top": 497, "height": 29, "left": 193}, "words": "性别:本品的药代动力学不因性别的不同而改变"}, {"probability": {"variance": 0.006009, "average": 0.966994, "min": 0.685634}, "location": {"width": 402, "top": 548, "height": 29, "left": 192}, "words": "种放本品的药代动力学不因种族的不同而改变"}, {"probability": {"variance": 0.008383, "average": 0.96544, "min": 0.557401}, "location": {"width": 769, "top": 592, "height": 39, "left": 193}, "words": "老年人:一项评价年龄与本品药代动力学关系的研究(口服本品1.0mg)显示老年人的AC"}, {"probability": {"variance": 0.001433, "average": 0.984234, "min": 0.807685}, "location": {"width": 772, "top": 631, "height": 38, "left": 187}, "words": "较健康年轻人的升高29.3%,这很可能是由于个体肾功能的差异所成的。老年人的用药"}, {"probability": {"variance": 0.022432, "average": 0.951758, "min": 0.393107}, "location": {"width": 291, "top": 678, "height": 28, "left": 187}, "words": "剂参看肾功能不全者的剂量调节"}, {"probability": {"variance": 0.001223, "average": 0.979949, "min": 0.910123}, "location": {"width": 99, "top": 743, "height": 25, "left": 188}, "words": "肾功能不全"}, {"probability": {"variance": 0.005697, "average": 0.973634, "min": 0.537148}, "location": {"width": 730, "top": 770, "height": 37, "left": 227}, "words": "在不同程度肾功能不全患者(无慢性乙型肝炎病毒感染):包括使用血液透析或持续性"}, {"probability": {"variance": 0.006522, "average": 0.96623, "min": 0.571704}, "location": {"width": 772, "top": 808, "height": 39, "left": 183}, "words": "便携式腹膜透析(CAPD)治疗的患者中,单次给药1mg本品后的药代动力学结果显示清除率"}, {"probability": {"variance": 0.00322, "average": 0.965671, "min": 0.763299}, "location": {"width": 763, "top": 848, "height": 38, "left": 181}, "words": "随肌酐清除率的降低而下降。单次给药1mg本品4小时后,血液透析能清除约给药剂量的"}, {"probability": {"variance": 0.002131, "average": 0.975442, "min": 0.829563}, "location": {"width": 492, "top": 890, "height": 36, "left": 187}, "words": "3%,给药7天后,CAPD治疗仅能清除约给药剂量的03%"}, {"probability": {"variance": 0.001089, "average": 0.9732, "min": 0.909798}, "location": {"width": 102, "top": 964, "height": 23, "left": 179}, "words": "肝功能不全"}, {"probability": {"variance": 0.011264, "average": 0.954061, "min": 0.477294}, "location": {"width": 730, "top": 989, "height": 38, "left": 222}, "words": "在中度和重度肝功能不全( Child-Pugh分级B或C)患者(不包括慢性乙肝病毒感染"}, {"probability": {"variance": 0.003291, "average": 0.975085, "min": 0.659946}, "location": {"width": 775, "top": 1026, "height": 40, "left": 176}, "words": "患者)中,研究了单次给药1mg后思替卡韦的药代动力学情况:肝功能不全患者与健康对照"}, {"probability": {"variance": 0.007268, "average": 0.957434, "min": 0.66731}, "location": {"width": 776, "top": 1065, "height": 40, "left": 175}, "words": "人群的恩替卡韦的药代动力学情况相似。因此,无需在肝功能不企患者中调节恩替卡韦的给"}, {"probability": {"variance": 0.009831, "average": 0.896059, "min": 0.762242}, "location": {"width": 59, "top": 1117, "height": 24, "left": 176}, "words": "药剂量"}, {"probability": {"variance": 0.07104, "average": 0.823639, "min": 0.362776}, "location": {"width": 85, "top": 1180, "height": 23, "left": 174}, "words": "肝移后"}, {"probability": {"variance": 0.019935, "average": 0.92353, "min": 0.529359}, "location": {"width": 732, "top": 1204, "height": 41, "left": 217}, "words": "日前尚不清楚本品在肝移植患者中的安全性和有效性,在一型的研究中,在使用"}, {"probability": {"variance": 0.024524, "average": 0.915362, "min": 0.377492}, "location": {"width": 780, "top": 1241, "height": 43, "left": 171}, "words": "稳定剂量的环孢酶素A(n5)或他克莫(n=4)治疗1感染肝移器中,由于肾功能"}, {"probability": {"variance": 0.013054, "average": 0.939783, "min": 0.551496}, "location": {"width": 777, "top": 1279, "height": 47, "left": 171}, "words": "的改变,本品在体内的总量约为肾功能正常的健康人的两倍,骚能的改变是导致本品在这"}, {"probability": {"variance": 0.015769, "average": 0.950684, "min": 0.408574}, "location": {"width": 778, "top": 1319, "height": 42, "left": 171}, "words": "些病人中浓度增加的原因本品与环孢酶素A或他克莫之间的药物动力学的相互作用尚"}, {"probability": {"variance": 0.028134, "average": 0.917287, "min": 0.411872}, "location": {"width": 782, "top": 1357, "height": 41, "left": 169}, "words": "被评价。这些患者在肝移植前、移植中使用本品或在肝植后锁用免抑制剂如环孢酶素A"}, {"probability": {"variance": 0.01378, "average": 0.950989, "min": 0.502426}, "location": {"width": 680, "top": 1395, "height": 40, "left": 174}, "words": "他克莫司的同时使用本品都有可能影响肾功能。故必须仔细评价患者的肾功能"}], "language": 3}